Pre-surgery chemotherapy plus targeted radiation for borderline pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed pancreatic cancer (adenocarcinoma) in the pancreas, and it’s in the pancreatic head or nearby areas.
- You are 18 years or older, and you are well enough to do daily activities (ECOG 0 or 1).
- Your cancer is “borderline resectable,” meaning imaging suggests it might be removed with surgery, as reviewed by a specialist team.
- You have not had chemotherapy or radiation for pancreatic cancer before.
- Your blood counts and organ labs are in a safe range (including enough white blood cells, platelets, hemoglobin, and kidney/liver function).
- Your bilirubin and CA 19.9 tumor marker are below the study limits (with allowed improvement after bile stent placement).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy before surgery for people with borderline resectable pancreatic cancer, to try to make surgery more successful. It also checks whether the study treatment is safe and helps tumors before the operation.
This trial tests giving chemotherapy before any surgery to people with borderline resectable or locally advanced pancreatic cancer. The goal is to shrink the tumor, which may make surgery more successful and improve outcomes.
This study tests a new drug (IBI343) combined with chemotherapy given before surgery for pancreatic cancer that is borderline resectable. The goal is to shrink the tumor enough so it can be removed with surgery, and this treatment focuses on a specific marker on cancer cells.
This trial tests whether giving proton radiation and chemotherapy before surgery can shrink or control “borderline resectable” pancreatic cancer so it can be removed more effectively. It may help by improving treatment response while planning for surgery afterward.
This study tests giving chemotherapy before surgery for pancreatic cancer that is borderline removable. The chemo is chosen based on your tumor's genetic signature, which may make the treatment more effective and help shrink the tumor enough for successful surgery.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before surgery to shrink the tumor in people with a specific type of pancreatic cancer. The goal is to make surgery more effective and improve outcomes.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.